TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06525428
Drug: standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT
Study: NCT05781542
Drug: Alum
Normalized name: Alum
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mcg
Study: NCT06334575
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks
Study: NCT05590923
Drug: OLA group: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).~DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC).
Study: NCT05590923
Drug: DEX group: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DEX group: dexamethasone (Decadron) 8 mg oral daily on days 2-4 after HEC (or days 2-3 after MEC)..~OLA group: olanzapine 10 mg oral each night on days 1-4 after HEC (or days 1-3 after MEC).
Study: NCT05758246
Drug: Fisetin-dose 1
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg once a day for one day.
Study: NCT05758246
Drug: Fisetin-dose 2
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg once a day for two days
Study: NCT05808608
Drug: AK104
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
Study: NCT05808608
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
Study: NCT05134688
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tocolytic to stop preterm labor
Study: NCT05865028
Drug: APG-157
Normalized name: APG-157
DrugBank: APG-157 (DB18683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 200mg (2 x 100mg pastilles) of APG-157 therapy orally (PO) three times daily during each 4-week cycle for up to three cycles. Cycle three is optional.
Study: NCT05992311
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive the montelukast treatment.
Study: NCT05164536
Drug: Amyvid
Normalized name: Amyvid
DrugBank: Florbetapir F-18 (DB09149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will undergo a single β-amyloid PET scan with Amyvid.
Study: NCT06348147
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered, once daily orally on Days 1-21 of a 28-day
Study: NCT06348147
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma, will be given subcutaneously once weekly on days 1, 8, and 15 of every 28 day cycle.
Study: NCT06348147
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is a glucocorticoid.
Study: NCT05291091
Drug: Sevasemten 10 mg
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT05291091
Drug: Sevasemten 5 mg
Normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT05291091
Drug: Sevasemten 12.5 mg
DrugBank: Sevasemten (DB18983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevasemten is administered orally once per day
Study: NCT05542381
Drug: Loteprednol Etabonate Ophthalmic Gel [Lotemax]
Normalized name: loteprednol etabonate Ophthalmic Gel [Lotemax]
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol (ophthalmic corticosteroid) will be stored in the clinic according to the instructions on the package. The vial will be stored upright between 15°-25°C (59°-77°F). In the clinic, the vial will be opened by the retina surgeon according to sterile procedure and administered (1 drop) by the surgeon immediately after the intravitreal injection.
Study: NCT05693935
Drug: TV-44749 - Dose level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
Study: NCT05693935
Drug: TV-44749 - Dose level 2
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
Study: NCT05693935
Drug: TV-44749 - Dose level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
Study: NCT05722522
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study: NCT05439629
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg/eye/time, 50 μl, intravitreal injection
Study: NCT05352763
Drug: simufilam
Normalized name: Simufilam
DrugBank: Simufilam (DB18817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: simufilam 100 mg oral tablets
Study: NCT06462079
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
Study: NCT05285397
Drug: Liraglutide Pen Injector [Saxenda]
Normalized name: liraglutide Pen Injector [Saxenda]
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection of GLP-1 agonist
Study: NCT04930627
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dosis depending on body weight: \<20 kg 5 mg 1x/day; 20-40 kg 2 x 5 mg; \>40 kg 2 x 10 mg
Study: NCT06247462
Drug: Placebo Corn Starch
Normalized name: Corn Starch
DrugBank: Corn (DB10572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
Study: NCT05165485
Drug: Revefenacin
Normalized name: Revefenacin
DrugBank: Revefenacin (DB11855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revefenacin 175 mcg administered once daily for 84 days via nebulization
Study: NCT05165485
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®
Study: NCT05165485
Drug: Revefenacin Placebo
DrugBank: Revefenacin (DB11855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for Revefenacin administered once daily for 84 days via nebulization
Study: NCT05165485
Drug: Tiotropium Placebo
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
Study: NCT06069726
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of atezolizumab will be given prior to resection.
Study: NCT05366335
Drug: Live Combined Bifidobacterium and Lactobacillus
Normalized name: Bifidobacterium animalis / Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
Study: NCT04940091
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
Study: NCT05681702
Drug: aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.
Study: NCT05681702
Drug: prasugrel or ticagrelor
Normalized name: Ticagrelor
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
Study: NCT05972681
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
Study: NCT05671510
Drug: Gotistobart
Normalized name: Gotistobart
DrugBank: Gotistobart (DB19100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
Study: NCT05671510
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
Study: NCT05873192
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT05873192
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05873192
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or given INJ
Study: NCT05570006
Drug: ABBV-668
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT06373146
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06373146
Drug: Mibavademab
Normalized name: Mibavademab
DrugBank: Mibavademab (DB16673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05132153
Drug: Milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will be given by nebulization
Study: NCT06373146
Drug: Tirzepatide-Placebo
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06373146
Drug: Mibavademab-Placebo
DrugBank: Mibavademab (DB16673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06783621
Drug: OnabotulinumtoxinA
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular Injections
Study: NCT06783621
Drug: KYBELLA
Normalized name: Kybella
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injections
Study: NCT06159621
Drug: PD-1inhibitor - LVGN 3616
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of one dose of LVGN 3616 - 300mg. Commercially available PD-1 inhibitor may be substituted.
Study: NCT06780865
Drug: Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine
Normalized name: Medicated Pad or Tape
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.
Study: NCT06781632
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine HCl - Betamethasone Sodium Phosphate - Clonidine HCl 5.0/0.4\*/0.015 mg/mL (The solution contains 0.53 mg of betamethasone sodium phosphate, equivalent to 0.4 mg of betamethasone)
Study: NCT06788444
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The propofol is administered until the patients loss of consciousness (loss of the eyelash refex). The 0.2 mg/kg esketamine is then administered by the anesthesiologist, but should be discontinued if the SBP ≥200 mmHg or the DBP ≥110 mmHg. After the administration of the 0.2 mg/kg esketamine is completed, the endoscopist will begin the colonoscopic procedure.
Study: NCT05861466
Drug: intra-vitreal injection of Ranibizumab
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
Study: NCT05019690
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
Study: NCT05019690
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
Study: NCT06223711
Drug: durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
Study: NCT05093855
Drug: BDB-001 Injection
Normalized name: BDB 001
DrugBank: BDB-001 (DB16480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
Study: NCT06785844
Drug: Botulinum Toxin A (Botox )
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum Toxin injection
Study: NCT06782529
Drug: Triamcinolone Acetonide Low Dose
Normalized name: triamcinolone acetonide Metered Dose Inhaler
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)
Study: NCT06782529
Drug: Triamcinolone Acetonide Standard Dose
Normalized name: triamcinolone acetonide Metered Dose Inhaler
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)
Study: NCT05723198
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT06783127
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib given according the clinical practice to BRCA positive mCRPC patients
Study: NCT05708521
Drug: Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery
Normalized name: Betagen brand of Betamethasone and Gentamicin
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
Study: NCT06048627
Drug: negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium fluoride mouthwash 250 ppm
Study: NCT05708521
Drug: Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
Study: NCT05414422
Drug: PCN-101
Normalized name: penicillin B
DrugBank: Pheneticillin (DB13337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion
Study: NCT05849038
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive baricitinib at a dose of 2 mg oral daily.
Study: NCT06435936
Drug: Single Ascending Dose of SAB-176
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose
Study: NCT04846634
Drug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT04846634
Drug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT04846634
Drug: Penpulimab+Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT04645602
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pill taken by mouth, once daily.
Study: NCT04645602
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection through a vein (IV).
Study: NCT05414500
Drug: Mogamulizumab
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT05414500
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT05224102
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 6-milligram (mg) faricimab intravitreal (IVT) injections, as described in the study arm descriptions for each study phase.
Study: NCT05676203
Drug: Standard Darolutamide
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2x600 mg/d as prescribed by the treating physician
Study: NCT05676203
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel
Study: NCT05931575
Drug: Fasudil hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Duration of intervention per patient: 22 days; Application scheme: one dose on day 1, two doses on days 2 - 21, one dose on day 22.
Study: NCT06783166
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Study: NCT06783166
Drug: Acetazolamide 500mg
Normalized name: ACETAZOLAMIDE 500MG CAP,SA
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
Study: NCT06095986
Drug: Aramchol meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
Study: NCT06701903
Drug: ITI-1284 10 mg
Normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.
Study: NCT06701903
Drug: ITI-1284 20 mg
Normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.
Study: NCT06294912
Drug: Artemether/lumefantrine
Normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to be administered orally as definitive antimalarial treatment.